Preliminary insights from the My Heart Your Heart trial showed that reconditioned pacemakers carried the same low infection risk as new devices when assessed out through 90 days. These early findings provide much needed data for those in lower-resource regions regarding the role for recycled devices.

Prior studies show that patient outcomes in AF can be improved with AF ablation. However, the AF journey for many patients can involve recurrence and there is a need to better optimize ablation approaches. New data from the CRRF-PeAF and PROMPT-AF trials helps inform patient management involving AF ablation. 

The VANISH2 trial demonstrated that catheter ablation was more effective than anti-arrhythmic drugs (sotalol or amio) as a first line therapy in VT in the context of ischemic cardiomyopathy. 

Appendage closure shown to reduce bleeding compared with oral anticoagulation  following AF ablation.

Open label study of 410 patients demonstrated that edoxaban was equally or more effective than warfarin at preventing stroke or systemic embolism at the expense of more major bleeding and GI bleeding. Follow-up studies with blinding are needed to better understand risk – benefit balance.